American Journal of Cardiovascular Drugs｜降压药物对高血压患者休息和运...（附源文）

Potential Protective Role of Blood Pressure-Lowering Drugs on the Balance between Hemostasis and Fibrinolysis in Hypertensive Patients at Rest and During Exercise

American Journal of Cardiovascular Drugs Review Article
Early Recent, Feb 04, 2019
10.1007/s40256-018-00316-2

本文由“天纳”临床学术信息人工智能系统自动翻译
点击文末“阅读原文”下载本文PDF

In patients with hypertension, the triad represented by endothelial dysfunction, platelet hyperactivity, and altered fibrinolytic function disturbs the equilibrium between hemostasis and fibrinolysis and translates into a hypercoagulable state, which underlies the risk of thrombotic complications. This article reviews the scientific evidence regarding some biological effects of antihypertensive drugs, which can protect patients from the adverse consequences of hypertensive disease, improving endothelial function, enhancing antioxidant activity, and restoring equilibrium between hemostatic and fibrinolytic factors. These protective effects appear not to be mediated through blood pressure reduction and are not shared by all molecules of the same pharmacological class.

在高血压患者中，以内皮功能障碍、血小板高活性和纤维蛋白溶解功能改变为代表的三联体扰乱了止血和纤维蛋白溶解之间的平衡，并转化为高凝状态，这是血栓并发症风险的基础。本文综述了抗高血压药物的一些生物学效应的科学证据，这些药物可以保护患者免受高血压疾病的不良后果，改善内皮功能，增强抗氧化活性，恢复止血和纤溶因子之间的平衡。这些保护作用似乎不是通过血压降低介导的，也不是由同一药理学类别的所有分子共享的。

Notes

Compliance with Ethical StandardsFundingNo sources of funding were used to assist with the preparation of this review.Conflict of interestDr A. Braschi has no conflicts of interest that are relevant to the content of this review.

References

1. Gleerup G, Vind J, Winther K. Platelet function and fibrinolytic activity during rest and exercise in borderline hypertensive patients. Eur J Clin Invest. 1995;25(4):266–70.CrossRefPubMedGoogle Scholar 2. Gavriilaki E, Gkaliagkousi E, Nikolaidou B, Triantafyllou G, Chatzopoulou F, Douma S. Increased thrombotic and impaired fibrinolytic response to acute exercise in patients with essential hypertension: the effect of treatment with an angiotensin II receptor blocker. J Hum Hypertens. 2014;28(10):606–9.CrossRefPubMedGoogle Scholar 3. El-Sayed MS, El-Sayed Ali Z, Ahmadizad S. Exercise and training effects on blood haemostasis in health and disease: an update. Sports Med. 2004;34(3):181–200.CrossRefPubMedGoogle Scholar 4. Ferguson EW, Bernier LL, Banta GR, Yu-Yahiro J, Schoomaker EB. Effects of exercise and conditioning on clotting and fibrinolytic activity in men. J Appl Physiol (1985). 1987;62(4):1416–21.Google Scholar 5. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.CrossRefPubMedPubMedCentralGoogle Scholar 6. Blood Pressure Lowering Treatment Trialists’ Collaboration, Turnbull F, Neal B, Pfeffer M, et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens. 2007;25(5):951–8.Google Scholar 7. Fogari R, Zoppi A. Antihypertensive drugs and fibrinolytic function. Am J Hypertens. 2006;19(12):1293–9.CrossRefPubMedGoogle Scholar 8. Skowasch D, Viktor A, Schneider-Schmitt M, Lüderitz B, Nickenig G, Bauriedel G. Differential antiplatelet effects of angiotensin converting enzyme inhibitors: comparison of ex vivo platelet aggregation in cardiovascular patients with ramipril, captopril and enalapril. Clin Res Cardiol. 2006;95(4):212–6.CrossRefPubMedGoogle Scholar 9. Sáez GT, Tormos C, Giner V, et al. Factors related to the impact of antihypertensive treatment in antioxidant activities and oxidative stress by-products in human hypertension. Am J Hypertens. 2004;17(9):809–16.CrossRefPubMedGoogle Scholar 10. Farkas K, Fábián E, Nagy L. Quinapril improves endothelial function in postmenopausal hypertensive patients. Kidney Blood Press Res. 2008;31(4):226–33.CrossRefPubMedGoogle Scholar 11. Staessen JA, Thijs L, Li Y, et al. ‘Beyond blood pressure’ means multiple risk factor intervention, not pleiotropic antihypertensive drugs. Curr Opin Cardiol. 2007;22(4):335–43.CrossRefPubMedGoogle Scholar 12. Punda A, Polić S, Rumboldt Z, Bagatin J, Marković V, Lukin A. Effects of atenolol and propranolol on platelet aggregation in moderate essential hypertension: randomized crossover trial. Croat Med J. 2005;46(2):219–24.PubMedGoogle Scholar 13. von zur Můhlen B, Millgård J, Lind L. Divergent effects of different beta-blocking agents on endothelium-dependent vasodilatation in the human forearm. Blood Press. 2000;9(5):287–92.Google Scholar 14. Jastrzebskal M, Widecka K, Naruszewicz M, et al. Effects of perindopril treatment on hemostatic function in patients with essential hypertension in relation to angiotensin converting enzyme (ACE) and plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms. Nutr Metab Cardiovasc Dis. 2004;14(5):259–69.CrossRefPubMedGoogle Scholar 15. Janczak-Bazan A.The hemostasis parameters and ACE gene polymorphism in patients with essential hypertension treated with perindopril. Ann Acad Med Stetin. 2006;52(1):51–61 (discussion 61–2).Google Scholar 16. Dell’Omo G, Penno G, Pucci L, et al. The vascular effects of doxazosin in hypertension complicated by metabolic syndrome. Coron Artery Dis. 2005;16(1):67–73.CrossRefPubMedGoogle Scholar 17. Baez MA, Garg DC, Jallad NS, Weidler DJ. Antihypertensive effect of doxazosin in hypertensive patients: comparison with atenolol. Br J Clin Pharmacol. 1986;21(Suppl 1):63S–7S.CrossRefPubMedPubMedCentralGoogle Scholar 18. Hernandez Hernandez R, Carvajal AR, Guerrero Pajuelo J, et al. The effect of doxazosin on platelet aggregation in normotensive subjects and patients with hypertension: an in vitro study. Am Heart J. 1991;121(1 Pt 2):389–94.CrossRefPubMedGoogle Scholar 19. Hernández Hernández R, Angeli-Greaves M, Carvajal AR, Guerrero Pajuelo J, Armas Padilla MC, Armas-Hernández MJ. Terazosin: ex vivo and in vitro platelet aggregation effects in patients with arterial hypertension. Am J Hypertens. 1996;9(5):437–44.CrossRefPubMedGoogle Scholar 20. Hernandez Hernandez R, Guerrero Pajuelo JR, Carvajal AR, et al. Evidence of an antiplatelet aggregation action of doxazosin in patients with hypertension: an ex vivo study. Am Heart J. 1991;121(1 Pt 2):395–401.CrossRefPubMedGoogle Scholar 21. Alarayyed NA, Cooper MB, Prichard BN, Betteridge DJ, Smith CC. In vitro adrenaline and collagen-induced mobilization of platelet calcium and its inhibition by naftopidil, doxazosin and nifedipine. Br J Clin Pharmacol. 1997;43(4):415–20.CrossRefPubMedPubMedCentralGoogle Scholar 22. Labiós M, Martínez M, Gabriel F, Guiral V, Ruiz-Aja S, Aznar J. Cytoplasmic free calcium mobilization in platelets, expression of P-selectin, phosphatidylserine, and microparticle formation, measured by whole blood flow cytometry, in hypertensive patients. Effect of doxazosin GITS. Thromb Res. 2006;117(4):403–9.CrossRefPubMedGoogle Scholar 23. Ikeda T, Nonaka Y, Goto A, Ishii M. Effects of prazosin on platelet aggregation and plasma beta-thromboglobulin in essential hypertension. Clin Pharmacol Ther. 1985;37(6):601–5.CrossRefPubMedGoogle Scholar 24. Okrucká A, Pechán J, Mikulecký M. Beta-thromboglobulin and platelet aggregation in essential hypertension and the influence of prazosin therapy. Cor Vasa. 1990;32(5):363–73.PubMedGoogle Scholar 25. Labiós M, Martínez M, Gabriel F, et al. Flow cytometric analysis of platelet activation in hypertensive patients. Effect of doxazosin. Thromb Res. 2003;110(4):203–8.CrossRefPubMedGoogle Scholar 26. Andersen P, Seljeflot I, Herzog A, Arnesen H, Hjermann I, Holme I. Effects of doxazosin and atenolol on atherothrombogenic risk profile in hypertensive middle-aged men. J Cardiovasc Pharmacol. 1998;31(5):677–83.CrossRefPubMedGoogle Scholar 27. Jansson JH, Johansson B, Boman K, Nilsson TK. Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol. Eur J Clin Pharmacol. 1991;40(4):321–6.CrossRefPubMedGoogle Scholar 28. Daae LN, Kierulf P, Brusletto B, Westheim A, Holme I, Syvertsen JO. The effect of doxazosin on blood pressure, lipids, fibrinogen and plasminogen activator inhibitor. A comparative study among smokers and non-smokers with essential hypertension. Tidsskr Nor Laegeforen. 1991;111(9):1102–5.Google Scholar 29. Giorda C, Appendino M, Mason MG, Imperiale E, Pagano G. Alpha 1-blocker doxazosin improves peripheral insulin sensitivity in diabetic hypertensive patients. Metabolism. 1995;44(5):673–6.CrossRefPubMedGoogle Scholar 30. Pollare T, Lithell H, Selinus I, Berne C. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia. 1988;31(7):415–20.CrossRefPubMedGoogle Scholar 31. Vague P, Juhan-Vague I, Aillaud MF, et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism. 1986;35(3):250–3.CrossRefPubMedGoogle Scholar 32. Zehetgruber M, Christ G, Gabriel H, et al. Effect of antihypertensive treatment with doxazosin on insulin sensitivity and fibrinolytic parameters. Thromb Haemost. 1998;79(2):378–82.CrossRefPubMedGoogle Scholar 33. Prichard BN, Gillam PM. Treatment of hypertension with propranolol. Br Med J. 1969;1(5635):7–16.CrossRefPubMedPubMedCentralGoogle Scholar 34. Pasternack A, Pörsti P, Pöyhönen L. Effect of pindolol and propranolol on renal function of patients with hypertension. Br J Clin Pharmacol. 1982;13(Suppl 2):241S–4S.CrossRefPubMedPubMedCentralGoogle Scholar 35. Serg M, Kampus P, Kals J, et al. Nebivolol and metoprolol: long-term effects on inflammation and oxidative stress in essential hypertension. Scand J Clin Lab Invest. 2012;72(5):427–32.CrossRefPubMedGoogle Scholar 36. Rizos E, Bairaktari E, Kostoula A, et al. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. J Cardiovasc Pharmacol Ther. 2003;8(2):127–34.CrossRefPubMedGoogle Scholar 37. Vyssoulis GP, Marinakis AG, Aznaouridis KA, et al. The impact of third-generation beta-blocker antihypertensive treatment on endothelial function and the prothrombotic state: effects of smoking. Am J Hypertens. 2004;17(7):582–9.CrossRefPubMedGoogle Scholar 38. Kerry R, Scrutton MC, Wallis RB. Beta-adrenoceptor antagonists and human platelets: relationship of effects to lipid solubility. Biochem Pharmacol. 1984;33(16):2615–22.CrossRefPubMedGoogle Scholar 39. Larsson PT, Wallén NH, Martinsson A, Egberg N, Hjemdahl P. Significance of platelet beta-adrenoceptors for platelet responses in vivo and in vitro. Thromb Haemost. 1992;68(6):687–93.CrossRefPubMedGoogle Scholar 40. Weksler BB, Gillick M, Pink J. Effect of propranolol on platelet function. Blood. 1977;49(2):185–96.PubMedGoogle Scholar 41. Markel A, Brook JG, Levy Y, Aviram M, Youdim MB. Increased platelet adhesion and aggregation in hypertensive patients: effect of atenolol. Br J Clin Pharmacol. 1983;16(6):663–8.CrossRefPubMedPubMedCentralGoogle Scholar 42. Srivastava KC. Influence of some beta blockers (pindolol, atenolol, timolol and metoprolol) on aggregation and arachidonic acid metabolism in human platelets. Prostaglandins Leukot Med. 1987;29(1):79–84.CrossRefPubMedGoogle Scholar 43. Lazebnik LB, Komissarenko IA, Guseĭnzade M, Shakurova MIu. Pharmacodynamic effects of lokren (betaxolol) in 3 month treatment of blood hypertension in elderly patients. Ter Arkh. 1998;70(6):44–7.Google Scholar 44. Small M, Douglas JT, Aherne GW, et al. Effects of the non-selective beta-adrenoceptor blocking agent, carteolol, on platelet function, blood coagulation and viscosity. Thromb Res. 1982;25(4):351–60.CrossRefPubMedGoogle Scholar 45. Giugliano D, Marfella R, Acampora R, Giunta R, Coppola L, D’Onofrio F. Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension. Diabetes Care. 1998;21(4):631–6.CrossRefPubMedGoogle Scholar 46. Gasser JA, Betterridge DJ. Comparison of the effects of carvedilol, propranolol, and verapamil on in vitro platelet function in healthy volunteers. J Cardiovasc Pharmacol. 1991;18(Suppl 4):S29–34.CrossRefPubMedGoogle Scholar 47. Okrucká A, Pechán J, Balazovjech I. The effect of short-term celiprolol therapy on platelet function in essential hypertension. Cardiology. 1993;82(6):399–404.CrossRefPubMedGoogle Scholar 48. Okrucká A, Pechán J, Kratochvílová H. Effect of long-term celiprolol therapy on haemostasis in essential hypertension. J Hum Hypertens. 1995;9(9):773–6.PubMedGoogle Scholar 49. Anfossi G, Trovati M, Lanzio M, Mularoni E, Massucco P, Emanuelli G. Effect of labetalol on human platelet function. Clin Exp Pharmacol Physiol. 1988;15(6):437–48.CrossRefPubMedGoogle Scholar 50. Celik T, Yuksel UC, Iyisoy A, et al. Effects of nebivolol on platelet activation in hypertensive patients: a comparative study with metoprolol. Int J Cardiol. 2007;116(2):206–11.CrossRefPubMedGoogle Scholar 51. Donaldson KM, Ayesu K, Francis JL, Challenor VF, Waller G. Effects of nifedipine and propranolol on whole blood platelet aggregation. Platelets. 1991;2(3):141–3.CrossRefPubMedGoogle Scholar 52. Savoia C, Touyz RM, Amiri F, Schiffrin EL. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension. 2008;51(2):432–9.CrossRefPubMedGoogle Scholar 53. Marfella R, Siniscalchi M, Nappo F, et al. Regression of carotid atherosclerosis by control of morning blood pressure peak in newly diagnosed hypertensive patients. Am J Hypertens. 2005;18(3):308–18.CrossRefPubMedGoogle Scholar 54. Jekell A, Malmqvist K, Wallén NH, Mörtsell D, Kahan T. Markers of inflammation, endothelial activation, and arterial stiffness in hypertensive heart disease and the effects of treatment: results from the SILVHIA study. J Cardiovasc Pharmacol. 2013;62(6):559–66.CrossRefPubMedGoogle Scholar 55. Celik T, Iyisoy A, Kursaklioglu H, et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens. 2006;24(3):591–6.CrossRefPubMedGoogle Scholar 56. Soardo G, Donnini D, Moretti M, Milocco C, Catena C, Sechi LA. Effects of antihypertensive drugs on alcohol-induced functional responses of cultured human endothelial cells. Hypertens Res. 2008;31(2):345–51.CrossRefPubMedGoogle Scholar 57. Fahlbusch SA, Tsikas D, Mehls C, et al. Effects of carvedilol on oxidative stress in human endothelial cells and healthy volunteers. Eur J Clin Pharmacol. 2004;60(2):83–8.CrossRefPubMedGoogle Scholar 58. Yue TL, Wang X, Gu JL, Ruffolo RR Jr, Feuerstein GZ. Carvedilol prevents low-density lipoprotein (LDL)-enhanced monocyte adhesion to endothelial cells by inhibition of LDL oxidation. Eur J Pharmacol. 1995;294(2–3):585–91.CrossRefPubMedGoogle Scholar 59. Haas MJ, Jurado-Flores M, Hammoud R, et al. The effects of known cardioprotective drugs on proinflammatory cytokine secretion from human coronary artery endothelial cells. Am J Ther. 2017.  https://doi.org/10.1097/mjt.0000000000000648(Epub ahead of print). 60. Garbin U, Fratta Pasini A, Stranieri C, et al. Effects of nebivolol on endothelial gene expression during oxidative stress in human umbilical vein endothelial cells. Mediators Inflamm. 2008;2008:367590.CrossRefPubMedPubMedCentralGoogle Scholar 61. González Maqueda I. Adrenoreceptors, endothelial function, and lipid profile: effects of atenolol, doxazosin, and carvedilol. Coron Artery Dis. 1994;5(11):909–18.Google Scholar 62. Xiaozhen H, Yun Z, Mei Z, Yu S. Effect of carvedilol on coronary flow reserve in patients with hypertensive left-ventricular hypertrophy. Blood Press. 2010;19(1):40–7.CrossRefPubMedGoogle Scholar 63. Kandavar R, Fernandez C, Sander GE, et al. Digital plethysmography and arginine metabolism in prehypertension: effect of nebivolol therapy. J Clin Hypertens (Greenwich). 2015;17(1):14–9.CrossRefGoogle Scholar 64. Neuman RB, Hayek SS, Poole JC, et al. Nitric oxide contributes to vasomotor tone in hypertensive African Americans treated with nebivolol and metoprolol. J Clin Hypertens (Greenwich). 2016;18(3):223–31.CrossRefGoogle Scholar 65. Mason RP, Kalinowski L, Jacob RF, Jacoby AM, Malinski T. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation. 2005;112(24):3795–801.CrossRefPubMedGoogle Scholar 66. Falciani M, Rinaldi B, D’Agostino B, et al. Effects of nebivolol on human platelet aggregation. J Cardiovasc Pharmacol. 2001;38(6):922–9.CrossRefPubMedGoogle Scholar 67. Saijonmaa O, Metsärinne K, Fyhrquist F. Carvedilol and its metabolites suppress endothelin-1 production in human endothelial cell culture. Blood Press. 1997;6(1):24–8.CrossRefPubMedGoogle Scholar 68. Ohlstein EH, Arleth AJ, Storer B, Romanic AM. Carvedilol inhibits endothelin-1 biosynthesis in cultured human coronary artery endothelial cells. J Mol Cell Cardiol. 1998;30(1):167–73.CrossRefPubMedGoogle Scholar 69. Seljeflot I, Arnesen H, Andersen P, Aspelin T, Kierulf P. Effects of doxazosin and atenolol on circulating endothelin-1 and von Willebrand factor in hypertensive middle-aged men. J Cardiovasc Pharmacol. 1999;34(4):584–8.CrossRefPubMedGoogle Scholar 70. Pasini AF, Garbin U, Stranieri C, et al. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. Am J Hypertens. 2008;21(11):1251–7.CrossRefPubMedGoogle Scholar 71. Simova II, Todorova-Konstantinova RR, Denchev SV. Effects of nebivolol versus bisoprolol on endothelial function in hypertensive patients. Exp Clin Cardiol. 2009;14(4):45–9.PubMedPubMedCentralGoogle Scholar 72. Zepeda RJ, Castillo R, Rodrigo R, et al. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension. Basic Clin Pharmacol Toxicol. 2012;111(5):309–16.CrossRefPubMedGoogle Scholar 73. Arosio E, De Marchi S, Prior M, Zannoni M, Lechi A. Effects of nebivolol and atenolol on small arteries and microcirculatory endothelium-dependent dilation in hypertensive patients undergoing isometric stress. J Hypertens. 2002;20(9):1793–7.CrossRefPubMedGoogle Scholar 74. Merchant N, Rahman ST, Ferdinand KC, Haque T, Umpierrez GE, Khan BV. Effects of nebivolol in obese African Americans with hypertension (NOAAH): markers of inflammation and obesity in response to exercise-induced stress. J Hum Hypertens. 2011;25(3):196–202.CrossRefPubMedGoogle Scholar 75. Tarighi B, Kurum T, Demir M, Azcan SN. The effects of nebivolol on fibrinolytic parameters in mild and moderate hypertensive patients. Can J Cardiol. 2007;23(8):651–5.CrossRefPubMedPubMedCentralGoogle Scholar 76. Stauffer BL, Dow CA, Diehl KJ, Bammert TD, Greiner JJ, DeSouza CA. Nebivolol, but not metoprolol, treatment improves endothelial fibrinolytic capacity in adults with elevated blood pressure. J Am Heart Assoc. 2017;6(11):e007437.CrossRefPubMedPubMedCentralGoogle Scholar 77. Levenson J, Le Quan Sang KH, Devynck MA, Gitel R, Simon A. The role of antihypertensive drugs in counteracting adverse influence on large arteries. Am Heart J. 1987;114(4 Pt 2):992–7.CrossRefPubMedGoogle Scholar 78. Davi’ G, Novo S, Pinto A, et al. Platelet activation after adrenergic stimulation in hypertensive patients: effects of acebutolol. Eur Heart J. 1983;4(5):295–9.CrossRefPubMedGoogle Scholar 79. Gomi T, Ikeda T, Shibuya Y, Nagao R. Effects of antihypertensive treatment on platelet function in essential hypertension. Hypertens Res. 2000;23(6):567–72.CrossRefPubMedGoogle Scholar 80. Knight CJ, Panesar M, Wilson DJ, et al. Different effects of calcium antagonists, nitrates, and beta-blockers on platelet function. Possible importance for the treatment of unstable angina. Circulation. 1997;95(1):125–32.Google Scholar 81. Boman K, Boman JH, Andersson J, Olofsson M, Dahlöf B. Effects of atenolol or losartan on fibrinolysis and von Willebrand factor in hypertensive patients with left ventricular hypertrophy. Clin Appl Thromb Hemost. 2010;16(2):146–52.CrossRefPubMedGoogle Scholar 82. Greer IA, Walker JJ, McLaren M, Calder AA, Forbes CD. A comparative study of the effects of adrenoceptor antagonists on platelet aggregation and thromboxane generation. Thromb Haemost. 1985;54(2):480–4.PubMedGoogle Scholar